Heidi A Hempel1, Nathan S Cuka1, Ibrahim Kulac1, John R Barber2, Toby C Cornish1, Elizabeth A Platz2,3,4, Angelo M De Marzo1,3,4, Karen S Sfanos1,3,4. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Mast cells are of interest in prostate cancer because they possess both pro- and anti-tumorigenic properties and are present in the tumor microenvironment. We studied the association of mast cell count and densities with prostate cancer recurrence using tissue microarrays (TMAs) for 462 men who recurred (cases) and 462 controls that were matched to the cases nested in a cohort of radical prostatectomy patients. METHODS: Dual-immunostaining for mast cell tryptase and epithelial cytokeratin-8 and whole slide image analysis were used to assess total mast cell number, mast cell density (mast cell number/tissue area), and mast cell number per epithelial or stromal area in TMA spots containing tumor (up to 4 per man). We used conditional logistic regression to estimate the odds ratio (OR) and 95% confidence interval of recurrence for the mean, minimum, and maximum mast cell parameters in tumor tissue among each man's TMA spots. RESULTS: After taking into account matching factors of age, race, Gleason sum, and pathologic stage, higher minimum mast cell density in the tumor (comparing highest to lowest quartiles: OR = 0.58, 95% CI 0.40-0.86; P-trend = 0.004) was associated with a lower risk of recurrence. Patterns for mast cell number and ratio of mast cell number to epithelial or stromal area were similar to those for mast cell density. CONCLUSIONS: Our results suggest that intratumoral mast cells may be protective against prostate cancer recurrence and could potentially serve as a prognostic biomarker after prostatectomy. Prostate 77: 412-424, 2017.
BACKGROUND: Mast cells are of interest in prostate cancer because they possess both pro- and anti-tumorigenic properties and are present in the tumor microenvironment. We studied the association of mast cell count and densities with prostate cancer recurrence using tissue microarrays (TMAs) for 462 men who recurred (cases) and 462 controls that were matched to the cases nested in a cohort of radical prostatectomy patients. METHODS: Dual-immunostaining for mast cell tryptase and epithelial cytokeratin-8 and whole slide image analysis were used to assess total mast cell number, mast cell density (mast cell number/tissue area), and mast cell number per epithelial or stromal area in TMA spots containing tumor (up to 4 per man). We used conditional logistic regression to estimate the odds ratio (OR) and 95% confidence interval of recurrence for the mean, minimum, and maximum mast cell parameters in tumor tissue among each man's TMA spots. RESULTS: After taking into account matching factors of age, race, Gleason sum, and pathologic stage, higher minimum mast cell density in the tumor (comparing highest to lowest quartiles: OR = 0.58, 95% CI 0.40-0.86; P-trend = 0.004) was associated with a lower risk of recurrence. Patterns for mast cell number and ratio of mast cell number to epithelial or stromal area were similar to those for mast cell density. CONCLUSIONS: Our results suggest that intratumoral mast cells may be protective against prostate cancer recurrence and could potentially serve as a prognostic biomarker after prostatectomy. Prostate 77: 412-424, 2017.
Authors: Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz Journal: Clin Chem Date: 2018-12-05 Impact factor: 8.327
Authors: Yiwen Zhang; Cindy Ke Zhou; Michelangelo Fiorentino; Ericka M Ebot; Emily M Rencsok; Katja Fall; Tamara L Lotan; Massimo Loda; Francesca Giunchi; Elizabeth A Platz; Angelo M De Marzo; Lorelei A Mucci Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-09-18 Impact factor: 4.254
Authors: Janielle P Maynard; Jiayun Lu; Igor Vidal; Jessica Hicks; Luke Mummert; Tamirat Ali; Ryan Kempski; Ayanna M Carter; Rebecca Y Sosa; Lauren B Peiffer; Corinne E Joshu; Tamara L Lotan; Angelo M De Marzo; Karen S Sfanos Journal: J Pathol Date: 2021-11-25 Impact factor: 7.996
Authors: Suraj Sangroula; Alan Y Baez Vasquez; Prakash Raut; Bright Obeng; Juyoung K Shim; Grace D Bagley; Bailey E West; John E Burnell; Marissa S Kinney; Christian M Potts; Sasha R Weller; Joshua B Kelley; Samuel T Hess; Julie A Gosse Journal: Toxicol Appl Pharmacol Date: 2020-08-21 Impact factor: 4.219
Authors: Bruno Felix-Patrício; Alexandre F Miranda; Jorge L Medeiros; Carla B M Gallo; Bianca M Gregório; Diogo B Souza; Waldemar S Costa; Francisco J B Sampaio Journal: Int Braz J Urol Date: 2017 Sep-Oct Impact factor: 1.541
Authors: Jack Mottahedeh; Michael C Haffner; Tristan R Grogan; Takao Hashimoto; Preston D Crowell; Himisha Beltran; Andrea Sboner; Rohan Bareja; David Esopi; William B Isaacs; Srinivasan Yegnasubramanian; Matthew B Rettig; David A Elashoff; Elizabeth A Platz; Angelo M De Marzo; Michael A Teitell; Andrew S Goldstein Journal: Cancer Metab Date: 2018-09-21